- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | Polyrizon Ltd. Announces Closing of $4.0 Million Registered Direct Offering and Private Placement | 3 | GlobeNewswire (USA) | ||
| Fr | Polyrizon Ltd. - 6-K, Report of foreign issuer | - | SEC Filings | ||
| Do | Polyrizon prices $4M registered direct offering | 1 | Seeking Alpha | ||
| Do | Polyrizon Ltd. Announces $4.0 Million Registered Direct Offering and Private Placement | 1 | GlobeNewswire (USA) | ||
| POLYRIZON Aktie jetzt für 0€ handeln | |||||
| Mi | Polyrizon Tumbles on Clinical Studies | 1 | Baystreet.ca | ||
| Mi | Polyrizon Ltd.: Polyrizon Completes All Five U.S. Site Contracts for NASARIX First-in-Human Allergy Study | 2 | GlobeNewswire (USA) | ||
| 20.08. | Polyrizon Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 20.08. | Polyrizon completes contracting with all five clinical sites | 1 | Investing.com | ||
| 20.08. | Polyrizon Ltd.: Polyrizon Completes Clinical Site Network for NASARIX Study and Advances Toward Patient Enrollment | 1 | GlobeNewswire (USA) | ||
| 13.07. | Polyrizon Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 02.07. | Polyrizon Advances on Test Results | 1 | Baystreet.ca | ||
| 02.07. | Polyrizon: Positive Studiendaten zur Biokompatibilität beflügeln die Aktie | - | Investing.com Deutsch | ||
| 02.07. | Polyrizon completes biocompatibility tests for allergy nasal spray | 1 | Investing.com | ||
| 02.07. | Polyrizon Ltd.: Polyrizon Announces Successful Results for NASARIX Biocompatibility Program, Supporting Advancement Towards First in Human Clinical Trial | 305 | GlobeNewswire (Europe) | Raanana, Israel, July 02, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the "Company" or "Polyrizon"), a development-stage biotech company specializing in the development of innovative intranasal... ► Artikel lesen | |
| 29.06. | Polyrizon Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 29.06. | Polyrizon erhält Zulassung für klinische Studie zu Allergen-Nasenspray | - | Investing.com Deutsch | ||
| 29.06. | Polyrizon Ltd.: Polyrizon Makes Strong Progress: Receives Central IRB Approval for its Allergy Blocker Clinical Trial | 282 | GlobeNewswire (Europe) | Raanana, Israel, June 29, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the "Company" or "Polyrizon"), a development-stage biotech company specializing in the development of innovative intranasal... ► Artikel lesen | |
| 17.06. | Polyrizon receives U.S. patent publication notice for nasal drug delivery platform | 4 | Seeking Alpha | ||
| 17.06. | Polyrizon Ltd.: Polyrizon Receives Notice of U.S. Patent Publication for Mucoadhesive Drug Delivery Platform | 408 | GlobeNewswire (Europe) | Raanana, Israel, June 17, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the "Company" or "Polyrizon"), a development-stage biotech company specializing in the development of innovative intranasal... ► Artikel lesen | |
| 15.06. | Polyrizon Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings |
1 2 3 4 Weiter >>
73 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 37,435 | -0,09 % | Jury Awards 10x Genomics Millions in Patent Lawsuit Against Qiagen Unit | ||
| NOVAVAX | 8,740 | -0,57 % | Novavax-Aktie: Ist das im Zuge von Moderna die nächste Kursrakete? Die MRNA Krebs-Impfstoff-Welle hat begonnen! | © Foto: Tara Winstead auf PexelsBei Moderna ging es zuletzt steil nach oben, sehr spektakulär. Und jetzt könnte Novavax nachziehen. Der Grund bei Moderna ist ein Paukenschlag aus der Krebsforschung... ► Artikel lesen | |
| PALATIN TECHNOLOGIES | 12,700 | 0,00 % | Wall Street Wire: StreetWatch: A $2.9 Billion Takeover Put a Spotlight on Relentless Hunger. Palatin Technologies Is Developing the Next Generation of the Drug That Seeks to Treat It | Rare-endocrine buyers have paid roughly $2.9 billion and approximately $10.0 billion for acquisitions in this area over the past four months. IMCIVREE, the only approved MC4R agonist for acquired... ► Artikel lesen | |
| BIOXXMED | 1,050 | 0,00 % | PTA-News: bioXXmed AG: Einladung zur Hauptversammlung | DJ PTA-News: bioXXmed AG: Einladung zur Hauptversammlung
Unternehmensmitteilung für den Kapitalmarkt
bioXXmed AG: Einladung zur Hauptversammlung
Heidelberg (pta000/20.07.2026/15:45... ► Artikel lesen | |
| OCUGEN | 1,174 | -0,17 % | Ocugen Announces First Patient Dosed in Phase 3 Registrational Trial of OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration | The single global Phase 3 trial, ArMaDa3 (NCT07770828), is the first pivotal gene therapy trial in geographic atrophy (GA)U.S. Food and Drug Administration (FDA) granted OCU410 Regenerative Medicine... ► Artikel lesen | |
| INOVIO PHARMACEUTICALS | 1,214 | -1,06 % | INOVIO Pharmaceuticals, Inc.: INOVIO Reports Second Quarter 2026 Financial Results and Recent Business Highlights | U.S. Food and Drug Administration (FDA) review of Biologics License Application (BLA) for INO-3107 as a treatment for Recurrent Respiratory Papillomatosis (RRP)... ► Artikel lesen | |
| COSCIENS BIOPHARMA | 4,515 | -1,31 % | COSCIENS Biopharma Inc. Reports Q2 2026 Results | TORONTO, ONTARIO, Aug. 11, 2026 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (TSX: CSCI) (OTCQB: CSCI.F) ("COSCIENS" or the "Company") today reported its financial and operating results for the second... ► Artikel lesen | |
| NUREXONE BIOLOGIC | 0,391 | -3,46 % | Keine von der FDA zugelassene Exosomentherapie: Warum NurExone eine große Marktchance adressiert | ||
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,114 | -3,80 % | PACB Cuts 2026 Outlook as Clinical Adoption Faces Its Crucial Test | ||
| REDHILL BIOPHARMA | 0,748 | +3,24 % | RedHill Biopharma Ltd.: RedHill Divests Talicia to Apotex for $18 Million Cash Upfront Plus Milestones to Fuel Strategic Growth Opportunities | Executes a major step in RedHill's strategic roadmap to fundamentally reposition the Company's commercial business toward new and larger product opportunities, revenue growth and an accelerated... ► Artikel lesen | |
| MOSAIC IMMUNOENGINEERING | - | - | Mosaic ImmunoEngineering Inc. - 10-Q, Quarterly Report | ||
| PHIO PHARMACEUTICALS | 1,080 | 0,00 % | Phio Pharmaceuticals Corp.: Phio Pharmaceuticals Secures U.S. Notice of Allowance for INTASYL Composition Selectively Targeting BRD4 Protein with Compound PH-894 | King of Prussia, Pennsylvania--(Newsfile Corp. - August 11, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical-stage biotechnology company developing immuno-oncology therapeutics based... ► Artikel lesen | |
| NOVOCURE | 14,935 | -3,30 % | Novocure Announces Upcoming Investor Events | Novocure (NASDAQ: NVCR) announced today that management will participate in two upcoming investor events.
Wells Fargo 21st Annual Healthcare Conference, September 9, 2026: Frank Leonard, Chief... ► Artikel lesen | |
| OCULAR THERAPEUTIX | 9,050 | -1,63 % | Ocular Therapeutix (OCUL): Faster Path To Approval Comes With Rising Costs | ||
| ORAGENICS | 0,510 | -0,97 % | Oragenics, Inc.: Oragenics Reports Continued Clinical Progress, Provides Regulatory and NYSE American Listing Update | SARASOTA, Fla., Aug. 28, 2026 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a clinical-stage biopharmaceutical company developing brain-targeted therapeutics through its proprietary intranasal... ► Artikel lesen |
POLYRIZON LTD gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 11,240 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu POLYRIZON LTD finden Sie auf Wallstreet Online.